SCHEDULE: Invus Group Discloses 6.5% Stake in DBV Technologies

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 19,310,005 ordinary shares, representing 6.5% of DBV Technologies S.A.

Summary

• Invus Public Equities, L.P., along with several affiliated entities including Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Raymond Debbane, have filed a Schedule 13G.
• As of March 31, 2026, these reporting persons collectively beneficially own 19,310,005 ordinary shares of DBV Technologies S.A.
• This holding represents 6.5% of the total outstanding ordinary shares.
• The shares are held through a combination of directly held ordinary shares and American Depositary Shares (ADSs), with each ADS representing five ordinary shares.
• Invus Public Equities directly holds 10,023,195 ordinary shares and 1,594,935 ADSs, totaling 17,997,870 ordinary shares.
• Avicenna Fund directly holds 262,427 ADSs, representing 1,312,135 ordinary shares.
• The filing indicates that the reporting persons do not hold these shares for the purpose of influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership stakes and does not provide new operational or financial information about the company itself.

Positives

• Significant stake held by a known investment group, potentially indicating confidence in the company's long-term prospects.
• The filing is an amendment to a Schedule 13G, suggesting a passive investment approach rather than an attempt to gain control.

Negatives

• The filing does not contain financial performance data or operational updates, limiting the assessment of the company's current health.
• The passive nature of the filing means it does not offer insights into strategic initiatives or future growth drivers from the reporting persons' perspective.

Risks

• The concentration of ownership by a single group could potentially lead to future strategic shifts or influence if their investment thesis changes.
• As a Schedule 13G filing, it does not detail the specific investment strategy or rationale behind acquiring this stake, leaving potential future actions open to interpretation.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the company.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where significant capital is often required for development and regulatory approval. This filing indicates a substantial passive investment by the Invus Group in DBV Technologies.

Stakeholder Impact

• Shareholders: The filing confirms a significant passive investment by a known investment group, which could be viewed positively as a sign of confidence, but does not directly impact current operations or shareholder value.
• Management: The filing reinforces that the reporting persons are not seeking to influence control, which may provide a degree of stability regarding ownership structure.
• Creditors: No direct impact on creditors is indicated by this ownership disclosure.

Next Steps

• The reporting persons will continue to monitor their investment in DBV Technologies S.A.
• Further filings may be required if ownership levels change significantly.

Key Dates

Keywords

DBV Technologies, Schedule 13G, Invus Public Equities, Raymond Debbane, Beneficial Ownership, Ordinary Shares, American Depositary Shares, SEC Filing, Investment Group